Technical Analysis for RIGL - Rigel Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 2.34 2.18% 0.05
RIGL closed up 2.18 percent on Friday, November 15, 2019, on 85 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical RIGL trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Boomer Buy Setup Bullish Swing Setup 2.18%
Inside Day Range Contraction 2.18%
Wide Bands Range Expansion 2.18%
Overbought Stochastic Strength 2.18%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Wide Bands Range Expansion 3.08%
Overbought Stochastic Strength 3.08%

Older signals for RIGL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel and small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for the treatment of rheumatoid arthritis; R343, an inhaled SYK inhibitor that is in Phase II clinical trials to treat asthma; R333, a topical dermatological janus kinase (JAK)/SYK inhibitor, which is in Phase II clinical trials for the treatment of discoid lupus erythematosus; and R348, a topical ophthalmic JAK/SYK inhibitor that is in Phase I clinical trials to treat keratoconjunctivitis sicca. The company also conducts preclinical studies for an oral activator of adenosine monophosphate activated protein kinase to enhance the body's energy utilization and restore muscle endurance in chronically ill subjects. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB to develop and commercialize oral SYK inhibitors; and Daiichi Sankyo to conduct research related to drug targets called ligases that control cancer cell proliferation through protein degradation, as well as a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.
Cancer Chemical Compounds Rheumatoid Arthritis Drug Development Asthma Enzymes Tyrosine Kinase Inhibitors Tyrosine Kinase Inflammatory And Autoimmune Diseases Janus Kinase Portola Pharmaceuticals Tyrosine Kinases
Is RIGL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.16
52 Week Low 1.56
Average Volume 1,493,931
200-Day Moving Average 2.1569
50-Day Moving Average 1.8704
20-Day Moving Average 2.1225
10-Day Moving Average 2.236
Average True Range 0.1419
ADX 43.86
+DI 27.6812
-DI 5.8486
Chandelier Exit (Long, 3 ATRs ) 1.9843
Chandelier Exit (Short, 3 ATRs ) 1.9857
Upper Bollinger Band 2.5142
Lower Bollinger Band 1.7308
Percent B (%b) 0.78
BandWidth 36.909305
MACD Line 0.1353
MACD Signal Line 0.1215
MACD Histogram 0.0138
Fundamentals Value
Market Cap 291.08 Million
Num Shares 124 Million
EPS -0.68
Price-to-Earnings (P/E) Ratio -3.44
Price-to-Sales 45.70
Price-to-Book 6.79
PEG Ratio -0.10
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.51
Resistance 3 (R3) 2.51 2.45 2.48
Resistance 2 (R2) 2.45 2.41 2.45 2.47
Resistance 1 (R1) 2.40 2.39 2.43 2.40 2.46
Pivot Point 2.34 2.34 2.36 2.34 2.34
Support 1 (S1) 2.29 2.30 2.32 2.29 2.22
Support 2 (S2) 2.23 2.28 2.23 2.21
Support 3 (S3) 2.18 2.23 2.20
Support 4 (S4) 2.18